Exscientia, with its World’s first AI-Designed Immuno-Oncology Drug to Enter Clinical Trials, Announces Investment of up to $525M
--$225 million Series D round closed with access up to an additional $300 million at Exscientia’s discretion, led by SoftBank Vision Fund 2
Exscientia, a clinical stage pharmatech company using artificial intelligence (AI) to design patient-based drugs, announced that it has completed a $225 million Series D funding round. SoftBank Vision Fund 2 led the Series D and was joined by previous round lead investors, Novo Holdings, GT Healthcare Capital and funds managed by Blackrock. Funding from the Series D round will be used to advance Exscientia’s proprietary pipeline through clinical testing as well as to continue expanding the technology platform toward autonomous drug design. In addition, SoftBank is providing an additional $300 million equity commitment that can be drawn at the Company’s discretion.
Exscientia uses AI across its platform from target identification through drug design and patient selection in order to engineer new precision medicines. The Company has more than 20 projects in development, including two currently in clinical trials, and has partnered with firms including Bristol-Myers Squibb, Bayer AG, and Sanofi, as well as several biotech firms. Among them, the innovative anti-tumor drug jointly developed by GT Apeiron Therapeutics and Exscientia has obtained excellent animal data and is now preparing for IND.
As the first financial investor to spot Exscientia potential, GT healthcare capital has established close collaboration with Exscientia and would continue to follow Exscientia in the future, helping it become the world’s leading AI pharmaceutical company, and further bringing rapid development and breakthroughs of the use of artificial intelligence in the biopharmaceutical field to the world.
SoftBank Vision Fund is a subsidiary of Softbank Group that specializes in growth capital and social impact investments. It is the world's largest technology-focused venture capital fund, with over $100 billion in capital.
About GT Healthcare Capital Partners
GT Healthcare Capital Partners (“GT Healthcare”) is an Asia-based private investment partnership that specializes in healthcare investments around the globe that aim to change technology landscapes. GT Healthcare intends to provide capital and scale expertise to healthcare businesses in Asia / Greater China.